The new four-story 20,000 m² facility will feature mammalian cell culture, messenger RNA and cell therapy services and be operational in 2026
Today, we announced plans to construct a new manufacturing facility at AGC Inc.’s Yokohama Technical Center in Japan. The new site is a part of our strategic growth strategy to create more high-quality pharmaceutical development and manufacturing services in the Asia region that can help meet the global demand for biologics and advanced therapy medicinal products (ATMPs). The facility is expected to be operational in 2026.
The new AGC Biologics Yokohama facility will offer pre-clinical through commercial services for mammalian-based protein biologics, cell therapies, and messenger RNA (mRNA). The site will house multiple 2,000 L single-use bioreactors and several 4,000 L or larger reactors for mammalian cell culture services, making it one of Japan’s largest* sites for mammalian-based manufacturing capacity once complete. (*AGC estimates)
AGC Biologics is building this facility thanks to a grant from the Japanese Ministry of Economy, Trade and Industry (METI) as part of the ministry’s initiative to develop biopharmaceutical manufacturing sites to strengthen vaccine production in the region (announced in October 2022). The total investment for the AGC Biologics Yokohama site is expected to be approximately 50 billion Japanese yen ($350,500,000 USD) and once fully operational it will employ 400 people.
Read full article on agcbio.com